Authors

Latest:

Payers have transformed the competitive marketplace, and biopharma companies need to regain their position as the authority on their products. To do this, they must establish new ways to anticipate, identify, and react to payer impressions of relevant evidence as they occur.

Latest:

Every major pharma company undertakes some form of diversity and inclusion work. However, that doesn’t mean it’s reaching the decision-makers, writes Stephen Frost.

Latest:

Matthew Sussman explores strategies for facilitating access to the timely patient data and analysis needed for successful value-based agreements between manufacturers, payer and provider organizations in 2020 and beyond.

Latest:

How exactly do pharma companies account for a gap between their hopes for a new drug and reality? Peter Harbin reports.

Latest:

Pharma companies are in a unique position to support and educate at-risk populations through patient services hubs.

Latest:

A centralized platform for assets supports the industry’s need for a greater volume of more diverse content, writes Callum Hawes.

Latest:

Latest:

With medical meetings and congresses going virtual in the face of COVID-19, how do pharma companies put together a strategic plan for a new format that meets goals while remaining sensitive to the broader environment?

Latest:

Pharma is built to overcome, but focus on fundamentals remains key.

Latest:

Whenever you hear “tried-and-true” used to describe a strategy, tactic, workshop, or any other fundamental step required to achieve market domination-ask the speaker what year it is.

Latest:

Cancer patients are now utilizing online programming made available by Patient Power as a source for expert analysis.

Latest:

Chance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.

Latest:

While there has been an increase in discourse concerning drug pricing transparency in recent years, there is still a degree of misunderstanding. This is due to the healthcare industry's numerous stakeholders and their compelling interests. This research done by Guidehouse aims to clear the picture.

Latest:

While there has been an increase in discourse concerning drug pricing transparency in recent years, there is still a degree of misunderstanding. This is due to the healthcare industry's numerous stakeholders and their compelling interests. This research done by Guidehouse aims to clear the picture.

Latest:

There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.

Latest:

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.

Latest:

There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.

Latest:

Following the COVID-19 pandemic, will drug companies be able to tame subdued anger against the industry by creating meaningful drug innovations?

Latest:

Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.

Latest:

With widescale collaboration among companies, academia, and the science community to solve COVID-19, we can hope that this crisis has acted as a catalyst to increase positive perception for the biopharma industry.

Latest:

With the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.

Latest:

With the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.

Latest:

With the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.

Latest:

Prescribers cite ways to alleviate systemic threats to their ability to serve.

Latest:

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.

Latest:

Taking stock of evolving practices in protecting the supply chain amid the pandemic, including partnering and planning for what’s next.

Latest:

With the role of Medical Information in pharma companies changing in recent years, this article outlines some current and future trends including globalization and the use of data to drive change.

Latest:

The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.

Latest:

Compliance officers from the life sciences industry joined together recently to discuss how the COVID-19 pandemic has changed the ways we live and work, and how those changes have impacted the life sciences industry as a whole and will continue to do so in the future.